Bio-Path Holdings, Inc. (BPTH)

Specializes in developing RNAi nanoparticle therapeutics for the treatment of cancer.

BPTH Stock Quote

Company Report

Bio-Path Holdings, Inc., headquartered in Bellaire, Texas, is a pioneering clinical and preclinical stage biopharmaceutical company focused on advancing RNAi nanoparticle drug development in oncology. Founded in 2007, the company specializes in leveraging its proprietary DNAbilize technology, which incorporates P-ethoxy, a DNA backbone modification designed to enhance drug delivery and protect therapeutic DNA from degradation.

At the forefront of its innovative pipeline is prexigebersen, Bio-Path's lead drug candidate currently undergoing Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Additionally, the company is developing Liposomal Bcl-2 for refractory/relapsed lymphoma and chronic lymphocytic leukemia, and Liposomal STAT3 in preclinical stages targeting pancreatic cancer, non-small cell lung cancer, and AML. Bio-Path Holdings also pursues prexigebersen-A for various solid tumors, underscoring its commitment to addressing diverse oncological challenges.

Bio-Path Holdings continues to innovate in the field of RNAi nanoparticle drug delivery, aiming to transform cancer treatment paradigms through its robust research and development efforts. With a strategic focus on expanding its therapeutic portfolio and advancing clinical programs, the company is dedicated to improving outcomes for patients worldwide facing complex malignancies.

BPTH EPS Chart

BPTH Revenue Chart

Stock Research

MCRB VTLE GREE PSA PSFE CARV RIOT

BPTH Chart

View interactive chart for BPTH

BPTH Profile

BPTH News

Analyst Ratings